Request for Information (RFI) on Data Collection for Emergency Clinical Trials and Interoperability Pilot; Extension of Comment Period, 69351-69352 [2022-25166]

Download as PDF Federal Register / Vol. 87, No. 222 / Friday, November 18, 2022 / Notices the FCPS product up to seventy pounds, but for January 2023, FCPS will remain only a lightweight offering. Overall, FCPS prices will increase 7.8 percent on average, with a 6.9 percent increase for FCPS-Retail and a 8.0 percent increase for FCPS-Commercial. New for 2023, the zoned prices for the existing ‘‘Local, 1, 2’’ Zone will be differentiated. The Local zone will be eliminated, and separate prices will be established for Zone 1 and Zone 2. No other structural changes are proposed. Nonstandard Fees (NSFs) are changing for our full network products for 2023. Ground products will see a price decrease in NSFs. khammond on DSKJM1Z7X2PROD with NOTICES F. USPS Retail Ground USPS Retail Ground, which is also slated for removal later in 2023 as part of the Postal Service’s expansion of FCPS and product simplification efforts, will remain on the competitive product list in January 2023. USPS Retail Ground prices will increase 6.4 percent overall on average. New for 2023, the zoned prices for the existing ‘‘Local, 1, 2’’ Zone will be differentiated. The Local zone will be eliminated, and separate prices will be established for Zone 1 and Zone 2. No other structural changes are proposed. Nonstandard Fees (NSFs) are changing for our full network products for 2023. Ground products will see a price decrease in NSFs. G. Domestic Extra Services Premium Forwarding Service (PFS) prices will increase 6.5 percent on average in 2023. The retail counter enrollment fee will increase to $25.45. The online enrollment option, introduced in 2014, will increase to $23.40. The weekly reshipment fee will increase to $25.45. PFS Local, which was introduced in 2019 for P.O. Box customers, will have an increased reshipment fee of $25.45. Prices for Adult Signature service will increase to $9.05 for the basic service and $9.35 for the person-specific service. Address Enhancement Service prices will remain the same for 2023. Competitive Post Office Box prices will be increasing 6.5 percent on average, within the existing price ranges. Package Intercept Service will increase to $17.00. The Pickup On Demand fee will increase to $26.50 for 2023. Premium Data Retention and Retrieval Service (USPS Tracking Plus), which was introduced in 2020, will not see a price change in 2023. New for 2023, the Postal Service is introducing a new Label Delivery Service under the Competitive Ancillary Services product, whereby residential and business customers can request return label VerDate Sep<11>2014 16:46 Nov 17, 2022 Jkt 259001 delivery for a $1.25 fee for certain products. II. International Products A. Expedited Services International expedited services include Global Express Guaranteed (GXG) and Priority Mail Express International (PMEI). Overall, GXG prices will rise by 4.9 percent, and PMEI will be subject to an overall 6.0 percent increase. Commercial Plus prices will be equivalent to Commercial Base. B. Priority Mail International The overall increase for Priority Mail International (PMI) will be 6.0 percent. Commercial Plus prices will be equivalent to Commercial Base. For Priority Mail Express International, weight-rated items tendered at retail counters will no longer be offered at prices equivalent to Priority Mail International for certain destinations and weight steps subject to certain requirements and conditions. The zoned prices based on origin ZIP Code for Priority Mail International destined to Canada will be collapsed into a single country group for Priority Mail International to Canada, and the related fee for the International Service Center (ISC) zone chart for Priority Mail International pieces destined to Canada will be eliminated. C. International Priority Airmail and International Surface Air Lift Published prices for International Priority Airmail (IPA) and International Surface Air Lift (ISAL) will increase by 3.5 percent and 12.0 percent, respectively. D. Airmail M-Bags The published prices for Airmail MBags will increase by 6.4 percent. E. First-Class Package International ServiceTM The overall increase for First-Class Package International Service (FCPIS) prices will be 6.5 percent. Commercial Plus prices will be equivalent to Commercial Base. F. International Ancillary Services and Special Services Prices for several international ancillary services will be increased, with an overall increase of 12.2 percent. Order The changes in prices and classes set forth herein shall be effective at 12:01 a.m. on January 22, 2023. We direct the Secretary to have this decision published in the Federal Register in accordance with 39 U.S.C. 3632(b)(2) PO 00000 Frm 00114 Fmt 4703 Sfmt 4703 69351 and direct management to file with the Postal Regulatory Commission appropriate notice of these changes. By The Governors: /s/ llllllllllllllllllll Roman Martinez IV, Chairman, Board of Governors. UNITED STATES POSTAL SERVICE OFFICE OF THE BOARD OF GOVERNORS CERTIFICATION OF GOVERNORS’ VOTE ON GOVERNORS’ DECISION NO. 22–6 Consistent with 39 U.S.C. 3632(a), I hereby certify that, on November 9, 2022, the Governors voted on adopting Governors’ Decision No. 22–6, and that a majority of the Governors then holding office voted in favor of that Decision. Date: November 9, 2022. /s/ llllllllllllllllllll Michael J. Elston, Secretary of the Board of Governors. [FR Doc. 2022–25179 Filed 11–17–22; 8:45 am] BILLING CODE 7710–12–P OFFICE OF SCIENCE AND TECHNOLOGY POLICY Request for Information (RFI) on Data Collection for Emergency Clinical Trials and Interoperability Pilot; Extension of Comment Period White House Office of Science and Technology Policy (OSTP). ACTION: Request for Information (RFI) on Data Collection for Emergency Clinical Trials and Interoperability Pilot; extension of comment period. AGENCY: SUMMARY: On October 28, 2022, the Office of Science and Technology Policy (OSTP) published in the Federal Register a document entitled ‘‘Request for Information (RFI) on Data Collection for Emergency Clinical Trials and Interoperability Pilot.’’ This RFI, issued by OSTP in partnership with the Office of the National Coordinator for Health Information Technology (ONC), invited comments on how to optimize data collection for clinical trials carried out across a range of institutions and sites, both in emergency settings and in the pre-emergency phase. OSTP and ONC are seeking input on viable technical strategies to distribute clinical trial protocols and capture clinical trial data using common application programming interfaces (APIs). OSTP and ONC also seek information about whether there is value in a pilot or demonstration project to operationalize data capture in the near term, for E:\FR\FM\18NON1.SGM 18NON1 khammond on DSKJM1Z7X2PROD with NOTICES 69352 Federal Register / Vol. 87, No. 222 / Friday, November 18, 2022 / Notices example within 6–12 months of the close of comments on the RFI. In response to requests by prospective commenters that they would benefit from additional time to adequately consider and respond to the RFI, OSTP has determined that an extension of the comment period until January 27, 2023 is appropriate. DATES: The end of the comment period for the document entitled ‘‘Request for Information (RFI) on Data Collection for Emergency Clinical Trials and Interoperability Pilot,’’ published on October 28, 2022 (87 FR 65259), is extended from December 27, 2022 to January 27, 2023. ADDRESSES: Comments submitted in response to 87 FR 65259 should be submitted electronically to datacollectionforclinicaltrials@ ostp.eop.gov and should include ‘‘Data Collection for Clinical Trials RFI’’ in the subject line of the email. Due to time constraints, mailed paper submissions will not be accepted, and electronic submissions received after the deadline cannot be ensured to be incorporated or taken into consideration. Instructions: Response to this RFI (87 FR 65259) is voluntary. Each responding entity (individual or organization) is requested to submit only one response. Please feel free to respond to one or as many prompts as you choose. Please be concise with your submissions, which must not exceed 10 pages in 12-point or larger font, with a page number on each page. Responses should include the name of the person(s) or organization(s) filing the comment. OSTP invites input from all stakeholders, including members of the public, representing all backgrounds and perspectives. In particular, OSTP is interested in input from health information technology (health IT) companies, app developers, clinical trial designers, and users of health IT products. Please indicate which of these stakeholder types, or what other description, best fits you as a respondent. If a comment is submitted on behalf of an organization, the individual respondent’s role in the organization may also be provided on a voluntary basis. Comments containing references, studies, research, and other empirical data that are not widely published should include copies or electronic links of the referenced materials. No business proprietary information, copyrighted information, or personally identifiable information should be submitted in response to this RFI (87 FR 65259). Please be aware that comments submitted in response to this RFI (87 FR VerDate Sep<11>2014 16:46 Nov 17, 2022 Jkt 259001 65259) may be posted on OSTP’s website or otherwise released publicly. In accordance with FAR 15.202(3), responses to this notice are not offers and cannot be accepted by the Federal Government to form a binding contract. Additionally, those submitting responses are solely responsible for all expenses associated with response preparation. FOR FURTHER INFORMATION CONTACT: For additional information, please direct questions to Grail Sipes at 202–456– 4444 or datacollectionforclinicaltrials@ ostp.eop.gov. SUPPLEMENTARY INFORMATION: In accordance with the 2022 National Biodefense Strategy for Countering Biological Threats, Enhancing Pandemic Preparedness, and Achieving Global Health Security (National Biodefense Strategy) and the American Pandemic Preparedness Plan (AP3), OSTP, in partnership with the National Security Council (NSC), is leading efforts to ensure that coordinated and large-scale clinical trials can be efficiently carried out across a range of institutions and sites to address outbreaks of disease and other emergencies.1 On October 28, 2022, OSTP, in partnership with ONC, published in the Federal Register a document inviting comments on how to optimize data collection for clinical trials carried out across a range of institutions and sites, both in emergency settings and in the pre-emergency phase (87 FR 65259). OSTP and ONC are seeking input on viable technical strategies to distribute clinical trial protocols and capture clinical trial data using common APIs. OSTP and ONC also seek information about whether there is value in a pilot or demonstration project to operationalize data capture in the near term, for example within 6–12 months of the close of comments on the RFI. The RFI was issued to seek input from a broad array of stakeholders on a range of topics related to data capture in the clinical trials context, including ways in which ONC standards and frameworks for interoperability might be leveraged to further the goals of the RFI. The document stated that the comment period would close on December 27, 2022. OSTP has received requests to extend the comment period. An extension of the comment period will provide additional opportunity for the public to consider the RFI and prepare comments to address the topics listed therein. Therefore, OSTP is extending 1 See Notice of Request for Information (RFI) on Clinical Research Infrastructure and Emergency Clinical Trials, published October 26, 2022 (87 FR 64821). PO 00000 Frm 00115 Fmt 4703 Sfmt 4703 the end of the comment period for the RFI from December 27, 2022 to January 27, 2023. Submitted by the White House Office of Science and Technology Policy on November 15, 2022. Stacy Murphy, Operations Manager. [FR Doc. 2022–25166 Filed 11–17–22; 8:45 am] BILLING CODE 3270–F1–P SECURITIES AND EXCHANGE COMMISSION [SEC File No. 270–811, OMB Control No. 3235–0767] Submission for OMB Review; Comment Request; Extension: Rule 204–5 Upon Written Request, Copies Available From: Securities and Exchange Commission, Office of FOIA Services, 100 F Street NE, Washington, DC 20549–2736 Notice is hereby given that, pursuant to the Paperwork Reduction Act of 1995 (44 U.S.C. 3501 et seq.), the Securities and Exchange Commission (the ‘‘Commission’’) has submitted to the Office of Management and Budget a request for extension of the previously approved collection of information discussed below. The title for the collection of information is: ‘‘Rule 204–5 under the Investment Advisers Act of 1940.’’ Rule 204–5 requires an investment adviser to deliver an electronic or paper version of the relationship summary to each retail investor before or at the time the adviser enters into an investment advisory contract with the retail investor. The purpose of the relationship summary is to assist retail investors in making an informed choice when choosing an investment firm and professional, and type of account. Retail investors can use the information required in the relationship summary to determine whether to hire or retain an investment adviser, as well as what types of accounts and services are appropriate for their needs. We estimate the total collection of information burden for rule 204–5 to be 1,137,413 annual aggregate hours per year, or 124 hours per respondent, for a total annual aggregate monetized cost of $77,344,061, or $8,402 per adviser. The likely respondents to this information collection are approximately 9,205 investment advisers registered with the Commission that are required to deliver a relationship summary to retail investors pursuant to rule 204–5. We also note E:\FR\FM\18NON1.SGM 18NON1

Agencies

Office of Science and Technology Policy

[Federal Register Volume 87, Number 222 (Friday, November 18, 2022)]
[Notices]
[Pages 69351-69352]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-25166]


=======================================================================
-----------------------------------------------------------------------

OFFICE OF SCIENCE AND TECHNOLOGY POLICY


Request for Information (RFI) on Data Collection for Emergency 
Clinical Trials and Interoperability Pilot; Extension of Comment Period

AGENCY: White House Office of Science and Technology Policy (OSTP).

ACTION: Request for Information (RFI) on Data Collection for Emergency 
Clinical Trials and Interoperability Pilot; extension of comment 
period.

-----------------------------------------------------------------------

SUMMARY: On October 28, 2022, the Office of Science and Technology 
Policy (OSTP) published in the Federal Register a document entitled 
``Request for Information (RFI) on Data Collection for Emergency 
Clinical Trials and Interoperability Pilot.'' This RFI, issued by OSTP 
in partnership with the Office of the National Coordinator for Health 
Information Technology (ONC), invited comments on how to optimize data 
collection for clinical trials carried out across a range of 
institutions and sites, both in emergency settings and in the pre-
emergency phase. OSTP and ONC are seeking input on viable technical 
strategies to distribute clinical trial protocols and capture clinical 
trial data using common application programming interfaces (APIs). OSTP 
and ONC also seek information about whether there is value in a pilot 
or demonstration project to operationalize data capture in the near 
term, for

[[Page 69352]]

example within 6-12 months of the close of comments on the RFI. In 
response to requests by prospective commenters that they would benefit 
from additional time to adequately consider and respond to the RFI, 
OSTP has determined that an extension of the comment period until 
January 27, 2023 is appropriate.

DATES: The end of the comment period for the document entitled 
``Request for Information (RFI) on Data Collection for Emergency 
Clinical Trials and Interoperability Pilot,'' published on October 28, 
2022 (87 FR 65259), is extended from December 27, 2022 to January 27, 
2023.

ADDRESSES: Comments submitted in response to 87 FR 65259 should be 
submitted electronically to 
[email protected] and should include ``Data 
Collection for Clinical Trials RFI'' in the subject line of the email. 
Due to time constraints, mailed paper submissions will not be accepted, 
and electronic submissions received after the deadline cannot be 
ensured to be incorporated or taken into consideration.
    Instructions: Response to this RFI (87 FR 65259) is voluntary. Each 
responding entity (individual or organization) is requested to submit 
only one response. Please feel free to respond to one or as many 
prompts as you choose. Please be concise with your submissions, which 
must not exceed 10 pages in 12-point or larger font, with a page number 
on each page. Responses should include the name of the person(s) or 
organization(s) filing the comment.
    OSTP invites input from all stakeholders, including members of the 
public, representing all backgrounds and perspectives. In particular, 
OSTP is interested in input from health information technology (health 
IT) companies, app developers, clinical trial designers, and users of 
health IT products. Please indicate which of these stakeholder types, 
or what other description, best fits you as a respondent. If a comment 
is submitted on behalf of an organization, the individual respondent's 
role in the organization may also be provided on a voluntary basis.
    Comments containing references, studies, research, and other 
empirical data that are not widely published should include copies or 
electronic links of the referenced materials. No business proprietary 
information, copyrighted information, or personally identifiable 
information should be submitted in response to this RFI (87 FR 65259). 
Please be aware that comments submitted in response to this RFI (87 FR 
65259) may be posted on OSTP's website or otherwise released publicly.
    In accordance with FAR 15.202(3), responses to this notice are not 
offers and cannot be accepted by the Federal Government to form a 
binding contract. Additionally, those submitting responses are solely 
responsible for all expenses associated with response preparation.

FOR FURTHER INFORMATION CONTACT: For additional information, please 
direct questions to Grail Sipes at 202-456- 4444 or 
[email protected].

SUPPLEMENTARY INFORMATION: In accordance with the 2022 National 
Biodefense Strategy for Countering Biological Threats, Enhancing 
Pandemic Preparedness, and Achieving Global Health Security (National 
Biodefense Strategy) and the American Pandemic Preparedness Plan (AP3), 
OSTP, in partnership with the National Security Council (NSC), is 
leading efforts to ensure that coordinated and large-scale clinical 
trials can be efficiently carried out across a range of institutions 
and sites to address outbreaks of disease and other emergencies.\1\ On 
October 28, 2022, OSTP, in partnership with ONC, published in the 
Federal Register a document inviting comments on how to optimize data 
collection for clinical trials carried out across a range of 
institutions and sites, both in emergency settings and in the pre-
emergency phase (87 FR 65259). OSTP and ONC are seeking input on viable 
technical strategies to distribute clinical trial protocols and capture 
clinical trial data using common APIs. OSTP and ONC also seek 
information about whether there is value in a pilot or demonstration 
project to operationalize data capture in the near term, for example 
within 6-12 months of the close of comments on the RFI. The RFI was 
issued to seek input from a broad array of stakeholders on a range of 
topics related to data capture in the clinical trials context, 
including ways in which ONC standards and frameworks for 
interoperability might be leveraged to further the goals of the RFI. 
The document stated that the comment period would close on December 27, 
2022. OSTP has received requests to extend the comment period. An 
extension of the comment period will provide additional opportunity for 
the public to consider the RFI and prepare comments to address the 
topics listed therein. Therefore, OSTP is extending the end of the 
comment period for the RFI from December 27, 2022 to January 27, 2023.
---------------------------------------------------------------------------

    \1\ See Notice of Request for Information (RFI) on Clinical 
Research Infrastructure and Emergency Clinical Trials, published 
October 26, 2022 (87 FR 64821).

    Submitted by the White House Office of Science and Technology 
Policy on November 15, 2022.
Stacy Murphy,
Operations Manager.
[FR Doc. 2022-25166 Filed 11-17-22; 8:45 am]
BILLING CODE 3270-F1-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.